What is the therapeutic effect of intravenous human immunoglobulin (Yimmugo)?

Intravenous human immunoglobulin (Yimmugo) is a drug for the treatment of primary humoral immunodeficiency (PI), and its therapeutic effect has been fully verified in clinical studies. According to the approval of the U.S.Food and Drug Administration (FDA), Yimmugo is suitable for PI patients aged 2 years and above. This group is usually prone to infections due to immune system dysfunction. Yimmugo is extracted from pooled plasma donated by healthy volunteers and can provide a broad spectrum of IgG antibodies to enhance patients' defense against various infectious agents.

In a pivotal Phase 3 clinical study, researchers evaluated the efficacy and safety of Yimmugo in 67 patients with primary humoral immunodeficiency. The study showed that during a 12-month observation period, patients received Yimmugo at doses of 0.2 to 0.8 g/kg of body weight every 3 to 4 weeks, with the primary outcome measure being the rate of serious bacterial infection (SBI). The results showed that the incidence rate of acute SBI was 0.07, which was well below the expected standard of less than one acute SBI per patient per year. This means that Yimmugo performs well in preventing bacterial infections, effectively reducing the patient's risk of infection.

In the study, althoughYimmugo was highly effective, some adverse reactions were also observed. The most common adverse reactions include headache, upper respiratory tract infection, fatigue, nausea, and increased blood pressure. Most of these side effects are mild and transient, and usually resolve after stopping the drug or adjusting the dose. Therefore, medical staff need to closely monitor the patient's response when performing treatment so that timely measures can be taken.

Yimmugo is supplied in single-dose vials with a 10% IgG concentration (100mg/mL) in solution, providing flexible use options. During treatment, ensure the patient is adequately hydrated and maintain an appropriate rate during infusion to reduce the risk of adverse reactions.

Reference materials:https://www.empr.com/home/news/fda-approves-yimmugo-for-primary-humoral-immunodefficiency/